Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ImmunoGen Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass. --(BUSINESS WIRE)--Dec. 31, 2019-- ImmunoGen Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on December 23, 2019 the compensation committee of the Company’s Board of Directors granted a
View HTML
Toggle Summary ImmunoGen Announces Accelerated Approval Pathway for Mirvetuximab Soravtansine in Ovarian Cancer
Top-Line Data from New Pivotal Single-Arm Trial, SORAYA, Expected in First Half of 2021 Confirmatory MIRASOL Trial for Mirvetuximab on Track to Start by Year-End Conference Call to be Held at 8:00 a.m. ET Today WALTHAM, Mass. --(BUSINESS WIRE)--Dec. 17, 2019-- ImmunoGen Inc.
View HTML
Toggle Summary ImmunoGen Presents Updated Findings from Phase 1 Study of IMGN632 at ASH Annual Meeting
Data Demonstrating Potential in AML and BPDCN Presented During Oral Presentation; Dose and Schedule Selected for Further Development Preclinical Combination Data Also Presented; Support Further Evaluation of IMGN632 Doublets and Triplet in AML WALTHAM, Mass. --(BUSINESS WIRE)--Dec.
View HTML
Toggle Summary ImmunoGen Announces Webcast of Presentation at the Piper Jaffray 31st Annual Healthcare Conference
WALTHAM, Mass. --(BUSINESS WIRE)--Nov. 26, 2019-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will participate in a fireside chat at the upcoming Piper Jaffray Healthcare
View HTML
Toggle Summary ImmunoGen to Present New Data on IMGN632 at 61st ASH Annual Meeting
Updated Phase 1 Data to be Highlighted in Oral Presentation Demonstrate Tolerable Safety Profile and Encouraging Activity in AML and BPDCN Preclinical Data for IMGN632 in Combination with Azacitidine and Venetoclax Support Clinical Evaluation of Doublets and Triplet in AML WALTHAM, Mass.
View HTML
Toggle Summary ImmunoGen Reports Recent Progress and Third Quarter 2019 Financial Results
Full Mirvetuximab Soravtansine Phase 3 FORWARD I and Initial Phase 1b FORWARD II Triplet Data Presented at ESMO Phase 3 MIRASOL Trial for Mirvetuximab in Ovarian Cancer on Track to Start by Year-End Updated IMGN632 AML and BPDCN Monotherapy Data Accepted as Oral Presentation at ASH Conference Call
View HTML
Toggle Summary ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2019 Operating Results
WALTHAM, Mass. --(BUSINESS WIRE)--Oct. 18, 2019-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m.
View HTML
Toggle Summary ImmunoGen Presents Initial Data from Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab Soravtansine in Combination with Carboplatin and Avastin® at ESMO
  FORWARD II Triplet Combination Demonstrates Encouraging Anti-Tumor Activity     Preliminary Findings Support Ongoing Study in Platinum-Sensitive Patients     WALTHAM, Mass. --(BUSINESS WIRE)--Sep. 29, 2019-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug
View HTML
Toggle Summary ImmunoGen Presents Full Data from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine in Ovarian Cancer at ESMO
  FORWARD I Did Not Meet Primary Endpoint of Progression-Free Survival; Promising Efficacy Results Seen in Folate Receptor Alpha (FRα) High Patients     Favorable Tolerability and Differentiated Safety Profile Observed with Mirvetuximab Monotherapy Compared to Chemotherapy     Exploratory Analyses
View HTML
Toggle Summary ImmunoGen to Present Full Data from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine and Initial Data from Phase 1b FORWARD II Triplet Cohort at ESMO
Conference Call to be Held at 8 a.m. ET on Monday, September 30 WALTHAM, Mass. --(BUSINESS WIRE)--Sep. 17, 2019-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that full data and additional exploratory
View HTML